Riskpilot← Back to searchSign inGet full accessENDOCONS AB
ABActiveOrg 5565815957Sysslomansgatan 41 BMedical specialists activities · NACE 8622Est. 19991 employees
Revenue 2025
SEK 251K
-26% vs 2024
EBITDA margin
-86.9%
+11% vs 2024
Equity ratio
17.6%
Financial strength
Net profit 2025
SEK -218K
+11% vs 2024
| Revenue | SEK 251K | -26% |
| EBITDA | SEK -218K | +11% |
| Net profit | SEK -218K | +11% |
| Total assets | SEK 17K | +42% |
| Equity | SEK 3K | +50% |
| Employees | 1 | — |
Legal name
ENDOCONS AB
Org number
5565815957
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
10 december 1999
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva medicinsk endokrinologisk konsultverksamhet samt äga och förvalta fast egendom ävensom idka därmed förenlig verksamhet.
Address
Sysslomansgatan 41 B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 449 | 635 | 582 | 457 | 340 | 311 | 337 | 251 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −86 | 171 | −150 | 101 | 4 | −29 | −133 | −174 | −246 | −218 |
| Depreciation & amort. | −0 | −20 | −20 | −27 | −27 | −27 | −7 | −7 | −0 | −0 |
| EBIT | −86 | 151 | −170 | 74 | −23 | −56 | −140 | −181 | −246 | −218 |
| Net financials | — | — | — | — | — | — | — | — | — | — |
| Profit before tax | −86 | 151 | −170 | 74 | −23 | −56 | −140 | −181 | −246 | −218 |
| Tax | −0 | −21 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −86 | 130 | −170 | 74 | −23 | −56 | −140 | −181 | −246 | −218 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 19 | 210 | 65 | 122 | 80 | 39 | 7 | 11 | 12 | 17 |
| Equity | −34 | 95 | −75 | −1 | −24 | −80 | −220 | −402 | 2 | 3 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 53 | 115 | 140 | 123 | 104 | 119 | 227 | 413 | 10 | 13 |
| Total debt | 53 | 115 | 140 | 123 | 104 | 119 | 227 | 413 | 10 | 13 |
EBITDA margin
-86.9%
This company
15.8%
Market median
-650% vs market
20162025
Equity ratio
17.6%
This company
38.2%
Market median
-54% vs market
20162025
Return on equity
-7266.7%
This company
18.4%
Market median
-39593% vs market
20162025
Net profit margin
-86.9%
This company
8.1%
Market median
-1173% vs market
20162025
Asset turnover
14.76×
This company
1.12×
Market median
+1218% vs market
20162025
Debt / equity
4.67×
This company
0.62×
Market median
-653% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PG Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ENDOCONS AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Gustaf Hammar | Audit | 0 companies |
| Nils Fredrik Wollesen Österberg | Deputy Board Member | 0 companies |
| Flemming Wollesen | Board of Directors | 0 companies |